Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Risk factor for toxic liver injury
Close the cap tightly after each use.
Internal links connect the product page with latest batches, lab reports, price list, and Learn references
Ginsenoside Rh4 alleviates non-alcoholic fatty liver disease (NAFLD) by modulating the gutliver axis
Another phase I/II clinical trial (NCT04019288) was designed and was commenced in 2019 to evaluate the safety and clinical benefit of durvalumab plus AVB-S6-500 (an AXL inhibitor) in platinum-resistant ovarian cancer patients
A highly glycolytic or pro-angiogenic product may worsen edema, vascular permeability, or ectopic tissue responses
US$ 24.87
US$ 29.04
US$ 21.48
